Twist Bioscience Corporation

NasdaqGS:TWST Stock Report

Market Cap: US$1.8b

Twist Bioscience Future Growth

Future criteria checks 1/6

Twist Bioscience is forecast to grow earnings and revenue by 19.3% and 17.6% per annum respectively. EPS is expected to grow by 21% per annum. Return on equity is forecast to be -38.3% in 3 years.

Key information

19.3%

Earnings growth rate

21.0%

EPS growth rate

Biotechs earnings growth21.2%
Revenue growth rate17.6%
Future return on equity-38.3%
Analyst coverage

Good

Last updated22 Apr 2024

Recent future growth updates

Recent updates

Twist Bioscience Corporation (NASDAQ:TWST) Surges 26% Yet Its Low P/S Is No Reason For Excitement

Feb 27
Twist Bioscience Corporation (NASDAQ:TWST) Surges 26% Yet Its Low P/S Is No Reason For Excitement

Twist Bioscience: Strong Performance In A Soft Market

Feb 07

Here's Why Shareholders May Want To Be Cautious With Increasing Twist Bioscience Corporation's (NASDAQ:TWST) CEO Pay Packet

Jan 31
Here's Why Shareholders May Want To Be Cautious With Increasing Twist Bioscience Corporation's (NASDAQ:TWST) CEO Pay Packet

We're Not Very Worried About Twist Bioscience's (NASDAQ:TWST) Cash Burn Rate

Jan 22
We're Not Very Worried About Twist Bioscience's (NASDAQ:TWST) Cash Burn Rate

Twist Bioscience Corporation's (NASDAQ:TWST) Price Is Right But Growth Is Lacking After Shares Rocket 44%

Dec 18
Twist Bioscience Corporation's (NASDAQ:TWST) Price Is Right But Growth Is Lacking After Shares Rocket 44%

Twist Bioscience (NASDAQ:TWST) Is In A Good Position To Deliver On Growth Plans

Oct 05
Twist Bioscience (NASDAQ:TWST) Is In A Good Position To Deliver On Growth Plans

We Think Twist Bioscience (NASDAQ:TWST) Can Afford To Drive Business Growth

Jul 07
We Think Twist Bioscience (NASDAQ:TWST) Can Afford To Drive Business Growth

Twist Biosciences collaborates with Enzolytics on monoclonal antibodies for viruses

Sep 16

Twist Bioscience: DNA Synthesis Leader Appealing 'Picks And Shovels' Play

Sep 02

Twist Bioscience: DNA Synthesis Leader Is Just Getting Started

Aug 08

Twist Bioscience/ Biotia sequencing assay granted FDA nod to detect COVID variants

Aug 02

Twist Biosciences to work with DNAnexus on sequencing-based diagnostic tests

Jul 13

Twist Bioscience, Ildong team up to discover antibodies for cancer therapies

Jun 30

Twist Bioscience: A First Take

May 26

Earnings and Revenue Growth Forecasts

NasdaqGS:TWST - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/2026431-109-74-513
9/30/2025354-159-93-698
9/30/2024293-180-105-918
12/31/2023262-206-129-111N/A
9/30/2023245-205-170-142N/A
6/30/2023235-209-165-123N/A
3/31/2023228-213-212-134N/A
12/31/2022216-214-233-132N/A
9/30/2022204-218-226-124N/A
6/30/2022184-208-251-158N/A
3/31/2022163-188-212-152N/A
12/31/2021146-165-170-134N/A
9/30/2021132-152-139-112N/A
6/30/2021127-135-124-103N/A
3/31/2021113-123-115-98N/A
12/31/2020101-117-144-132N/A
9/30/202090-140-152-142N/A
6/30/202073-147-152-140N/A
3/31/202066-147-153-139N/A
12/31/201960-141-116-101N/A
9/30/201954-108-103-88N/A
6/30/201947-96-93-81N/A
3/31/201940-86-84-76N/A
12/31/201833-77-76-72N/A
9/30/201825-71-70-66N/A
6/30/201820-68-67-61N/A
9/30/201711-59N/A-51N/A
9/30/20162-44N/A-39N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TWST is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TWST is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TWST is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TWST's revenue (17.6% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: TWST's revenue (17.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TWST is forecast to be unprofitable in 3 years.


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.